An analysis of current neutropenia therapies, including pegfilgrastim-Reference-Cited by-同舟云学术

An analysis of current neutropenia therapies, including pegfilgrastim

Published:2006-01 Issue: Volume:8 Page:S19-S28
ISSN:1098-3597
Container-title:Clinical Cornerstone
language:en
Short-container-title:Clinical Cornerstone

Author:

Gabrilove Janice L.

Publisher

Elsevier BV

Subject

General Medicine

Reference41 articles.

1. NCCN clinical practice guidelines in oncology: Myeloid growth factors in cancer treatment. Version 1.2006;National Comprehensive Cancer Network,2006

2. Neutropenia management with granulocyte colony-stimulating factors: From guidelines to nursing practice protocols;Dolan;Eur J Oncol Nurs,2005

3. Update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline;Smith;J Clin Oncol,2006

4. Current and future use of hematopoietic growth factors in cancer medicine;Mughal;Hematol Oncol.,2004

5. Neupogen (filgrastim),2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial;BMC Cancer;2022-05-13

2. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer;BMC Cancer;2021-06-02

3. Side effects of using granulocyte-colony stimulating factors as prophylaxis of febrile neutropenia in cancer patients: A systematic review;Critical Reviews in Oncology/Hematology;2021-01

4. Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer;Annals of Oncology;2017-09

5. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy;Journal of Cancer Research and Therapeutics;2017